21/03/2018
1
Acknowledge and pay tribute to the traditional territories of the peoples of Treaty 7, which include the Blackfoot Confederacy (comprised of the Siksika, the Piikuni, and the Kainai First Nations) as well as the Tsuut’ina First Nation, and the Stoney Nakoda (including Chiniki, Bearspaw, and Wesley First Nations). Together, we share this land, strive to live together, learn together, walk together, and grow together “in a good way.”
21/03/2018
2
THE BASICS
Objectives:
• Define “transgender”, the basics of transgender medicine and its challenges
• Select appropriate language and terminology in LGBTQ+ population
• Review social, medical and surgical transition
4
21/03/2018
3
PLANNING COMMITTEEChair
Ted Jablonski, MD CCFP FCFPClinical Assistant Professor, University of Calgary, Depart. of Family MedicineClinical Associate, Men’s Sexual Health Clinic, Southern Alberta Institute of UrologyMedical Director, Jablonski Sexual Health and Wellness Calgary, AB
Scientific committee
John Axler, MD CCFP FCFPAssistant Professor, Dept. of Family and Community Medicine,Director of Continuing Education for the Depart. of Community and Family Medicine, University of Toronto,Toronto, ON
Raymond Fung, MD FRCPCEndocrinologistMichael Garron Hospital, University of TorontoToronto, ON
Ed Kucharski, MD CCFPFamily Physician, South East Toronto Family Health TeamMichael Garron Hospital, Cancer Care Ontario, Toronto, ON
Joe Raiche, MD FRCPCAssistant Clinical Professor, Dept. of Psychiatry, University of CalgaryPsychiatrist, Foothills Medical CentreCalgary, AB
Reviewers
Brian Craig, MD CCFP FCFPAssistant Clinical Professor, Dept. of Family Medicine,Memorial University, Saint John Regional Hospital,Saint John, NB
Lydia Hatcher, MD CCFP FCFPAssociate Clinical Professor of Family Medicine,McMaster University, Chief of Family Medicine, St Joseph's Healthcare,Hamilton, ON
Larry McClure, MD CCFP FCFPFamily Physician,Parksville, BC
Daniel Ngui, MD CCFP FCFPClinical Associate Professor, University of British Columbia,Department of Family Medicine,Clinical Lead, Fraser Street Medical,Vancouver, BC
Kevin Saunders, MD CCFPRivergrove Medical Clinic, The Wellness Institute,Winnipeg, MB
Richard Ward, MD CCFP FCFP Clinical Associate Professor, University of Calgary,Medical Director, Primary Care, Alberta Health Services,Albert, BC
Special Thanks Jorge L. Pinzon, M.D., FRCPC, FAAP, FSAHMPediatrician - Adolescent Medicine - Alberta Children's HospitalClinical Associate Professor of Pediatrics and Psychiatry - University of Calgary
5
Faculty/Presenter Disclosure• Faculty: Dr. Ted Jablonski, MD CCFP FCFP
• Relationships with financial interests:Principal Investigator (2016 – 2018)Principal Investigator in Clinical studies funded by Pfizer, Lilly, CortriaSpeaker’s Bureau, Advisory Board HonorariaAbbott Laboratories, Aralez (Tribute), AstraZeneca, Bayer, Boehringer‐Ingelheim, Bristol‐Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen‐Ortho, Lundbeck, Merck Frosst, Mylan, Novartis, Paladin labs, Pfizer, Sanofi‐Aventis, Schering, Servier, Shire, Solvay, Takeda, Valeant, Watson and media companies Antibody, CTC Communications, Edelman, mdBriefCaseMedPlan, Meducom, RxMedia , Science and Medicine
21/03/2018
4
PRESENTER DISCLOSURE
Dr. Ted Jablonski, MD CCFP FCFP #91934Conflict of Interest Declaration / Disclosure 2017
Principal Investigator (2015 – 2017)Principal Investigator in Clinical studies funded by Pfizer, Lilly, Cortria
Speaker’s Bureau, Advisory Board HonorariaAbbott Laboratories, Aralez (Tribute), AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Merck Frosst, Mylan, Novartis, Paladin labs, Pfizer, Sanofi-Aventis, Schering, Servier, Shire, Solvay, Takeda, Valeant, Watson and media companies Antibody, CTC Communications, Edelman, mdBriefCase MedPlan, Meducom, RxMedia , Science and Medicine
7
DISCLOSURE OF COMMERCIAL SUPPORT
• This program has received financial support from the Alliance for Best Practices in Health Education (ABPHE) not-for-profit organization
• This program has received in-kind support from liV Medical Communications & Training Agency
• Potential for conflict(s) of interest• Ted Jablonski has received support from ABPHE
• Ted Jablonski has not received funding from any commercial organization which may benefit from the content of this program
8
21/03/2018
5
MITIGATING POTENTIAL BIAS
• The information presented in this CME program is based on the literature available – evidence or expert opinion
• This CME program and its material is peer reviewed and all the recommendations involving clinical medicine are based on evidence that is accepted within the profession; and all scientific research referred to, reported, or used in the CME/CPD activity in support or justification of patient care recommendations conforms to the generally accepted standards
9
TRANSGENDER HEALTH
10
21/03/2018
6
Q&A
11
What is Gender?1
What is the best description of gender identity?2
GENDER
12
WHO definition
Gender refers to the socially constructed characteristics of women and men – such as norms, roles and relationships of and between groups of women and men. It varies from society to society and can be changed.
21/03/2018
7
GENDER IDENTITY
• Inherent sense of being male, female, or along gender non-binary spectrum
13
Q&A
14
What does the mnemonic LGBTQQIP2SAA stand for?1
21/03/2018
8
LGBTQQIP2SAA
15
Lesbian
Gay
Bisexual
Transgender
Queer
Questioning
Intersex
Pansexual
2 Spirited
Asexual
Ally
Q&A
16
What is the definition of TRANSGENDER?1
21/03/2018
9
TRANSGENDER
17
A marked incongruence between one’s experienced / expressed gender and assigned gender at birth
Q&A
18
Then what is Gender Dysphoria?1
21/03/2018
10
GENDER DYSPHORIA
• Previously called Gender Identity Disorder (GID)
• Gender dysphoria involves a conflict between a person's physical or assigned gender and the gender with which he/she/they identify
• People with gender dysphoria may often experience significant distress and/or problems functioning associated with this conflict
• Gender dysphoria is not the same as gender nonconformity (Gender variance, or gender nonconformity, is behavior or gender expression by an individual that does not match masculine and feminine gender norms)
19
DSM 5 CRITERIA
A marked incongruence between one’s experienced/expressed gender and
assigned gender, of at least 6 months’ duration, as manifested by at least
two of the following:
1. Incongruence between preferred gender and natal sex characteristics
2. Wish to prevent or remove natal sex characteristics
3. Desire for sex characteristics of alternative gender
4. Desire to be an alternative gender
5. Wants to be treated as an alternative gender
6. Have feelings and reactions of alternative gender
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. (Arlington, Va. : American Psychiatric Publishing, c2013., 2013) 20
21/03/2018
11
Q&A
21
What is NOT Transgender?1
TRANSGENDER IS NOT…..
• Transvestite / Transvestic fetishism
• Drag queen / king
• Cross dresser
• Gender role non-conformity
• Body Dysmorphic Disorder
• Dissociative Disorders
• Psychosis
22
21/03/2018
12
Q&A
23
How many transgender people do you have in your practice? (Are you sure?)
1
PREVALENCE
US 0.3 – 0.5% of population reported Transgender (2004-09)
UK 1% reported gender variant (2012)
Historic stats quoted in past “International estimate” (grossly underestimated) • F to M (Female to Male) 1 in 30,000• M to F (Male to Female) 1 in 7 - 12,000
• In the United States, it is estimated that roughly 1.4 million adults identify as transgender
24https://williamsinstitute.law.ucla.edu/category/research/census-lgbt-demographics-studies/
21/03/2018
13
Q&A
25
What names and pronouns should I use for my transgender patients?
1
WHAT NAMES AND PRONOUNS TO USE WITH YOUR PATIENT?
JUST ASK!
• What is your legal name?
• What name would you prefer to be called?
• What pronouns would you prefer for yourself (e.g. he, him, his / she, her, hers / they, them, theirs / other) Please specify:
• If not sure calling someone in from the waiting room, just use their last name.
26
21/03/2018
14
GENDER IDENTITY
What is your current gender identity? (Check all that apply)
• Male
• Female
• Female-to-Male (FTM)/Transgender Male/Trans Man
• Male-to-Female (MTF)/Transgender Female/Trans Woman
• Genderqueer, neither exclusively male nor female
• Additional Gender Category/(or Other), please specify
• Decline to Answer
• What sex were you assigned at birth on your original birth certificate?
(Check one) MALE FEMALE
27
Q&A
28
Is defining sexual orientation needed to determine if my patient is transgender?1
21/03/2018
15
GENDER VS SEXUALITY
29
Q&A
30
To what degree does transition impact the overall life of transgender patients?1
21/03/2018
16
OUTCOMES
Meta analysis of 28 studies with 1833 trans patients. Overall regret rate is 2.2% *
Murad, M. H. et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin. Endocrinol. (Oxf) 72, 214–231 (2010)
Level of significant improvement following hormone therapy and/or gender reassignment surgery (GRS)
Gender dysphoria 80%
Psychological symptoms (depression, anxiety, etc.)
78%
Quality of Life 80%
Sexual functioning 72%
31
Q&A
32
Are there any unique health risks seen with transgender patients prior to and during transition?
1
21/03/2018
17
MEDICAL COMORBIDITIES
Physical
• PCOS (40% of transmen pre-
transition)
• HIV and STIs (3X higher risk)
• Illegal drug use (3X higher
risk)
Psychiatric
• Mood disorders (27%)
• Anxiety disorders (17-31%)
• Personality disorders (15%)
• Substance use disorders (8%)
• Autism spectrum disorder (~5%)
• Suicidal ideation (35%); self-harm (37%); suicide attempts (8X higher)
33
PSYCHOSOCIAL COMORBIDITIES
Socioeconomic
• Higher risk of poor social supports
• Lack of income
• Lower education
• Overrepresented in the homeless population (25-40%)
• More likely to face school victimization (40%)
34Claes, L. et al. Non-suicidal self-injury in trans people: associations with psychological symptoms, victimization, interpersonal functioning, and perceived social support. J Sex Med 12, 168–179 (2015)
21/03/2018
18
Q&A
35
How do patients transition?1
Very individualized approach
SOCIAL TRANSITION
MEDICAL TRANSITION – Hormonal / Surgical
36
21/03/2018
19
37
Feminizing MasculinizingHormonal Blockade Leuprolide (GnRH agonist) Leuprolide (GnRH agonist)
Spironolactone
Cyproterone
Finasteride
Hormonal Estradiol Testosterone
? Progesterone
Surgical AugmentationBreast reduction / Male chest
contouring
Tracheal shaving Hysterectomy +/- BSO
Facial feminization
Vaginoplasty Phalloplasty
Orchiectomy Metoidioplasty
OPTIONS FOR MEDICAL TRANSITION
CRITERIA FOR HORMONE THERAPY
Longstanding pattern of gender non-conformity or dysphoria
No confounding psychological, medical, or social problems that would affect treatment
Informed consent
Age of majority in given country
If significant medical or mental health concerns, they must be reasonably well controlled
For adolescents
Gender dysphoria emerged or worsened with puberty
38Coleman, E. et al. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. International Journal of Transgenderism 13, 165–232 (2012)
21/03/2018
20
BEFORE STARTING HORMONES…
• Ask if they know if anyone who has transitioned and if they had any challenges?
• Assess if patient has adequate social supports? Who have they disclosed to? How to they plan on disclosing?
• Need help with connecting patient to community resources, support groups, etc.
• Counsel patient about anticipated hormone effects and risks of hormones
• Assess and counsel on fertility preservation options – if patient is interested
39
Suppress:
Anti-androgen• Androgen receptor blocker
• GnRH agonists
− Decrease testosterone
production by suppressing
GnRH-LH- testosterone axis
No prospective randomized
controlled trials on effectiveness
of different regimens
HORMONAL THERAPY: FEMINIZING
Hembree, Wylie et al, Endocrine treatment of Transsexual Persons: An Endocrine Society Clinical practice guideline. Journal Clin Endocrinology and metabolism; 94:3132-3154, 2009. 40
Enhance:
Estrogen− (Progesterone)
21/03/2018
21
HORMONAL THERAPY: FEMINIZING
VANESSARequesting to be a new patient in your practice
− 31 year old, Accountant
− Marital status: separated
Past Medical History:
− Major depression / generalized anxiety
− Substance abuse
MEDS: Zoplicone 7.5mg at hsSertraline 150mg OD
41
HORMONAL THERAPY: FEMINIZING
VANESSA
Hormonal therapy
− Estradiol 2 mg
− Spironolactone 200mg
42
21/03/2018
22
HORMONAL THERAPY: FEMINIZING
VANESSA
LAB REPORT (brought in by patient)
• Estradiol 188 pmol/L (female range follicular: 77 – 921, midcycle 139- 2382)
• Testosterone 5.7 nmol/L (female range < 1.8)
43
http://www.rainbowhealthontario.ca/TransHealthGuide/pdf/fem-ht-expectedeffectsguide.pdf 44
21/03/2018
23
Q&A
45
What are the most common challenges with hormonal feminization?
1
CHALLENGES
Lack of clinical therapeutic effect
Mood / libido
sexual function
side effects
increased risks in older patient
46
21/03/2018
24
VANESSA (REVISITED)
You have taken her into your practice, hormones have been titrated and you have started referral for gender transition related surgery
HORMONES
− Estradiol titrated to 4mg
− Spironolactone titrated to 300mg
LAB
− Estradiol 302 pmol/L (female follicular: 77–921, midcycle 139-2382)
− Testosterone 0.9 nmol/L (female < 1.8)
47
LET’S REALLY TRANSITION….
48
21/03/2018
25
SAM
24 year old Transman healthy, construction worker in relationship
Past Medical History
• Smoker, just quit
• MDD / GAD in past
MEDS
• Started TESTOSTERONE (bought at gym)
• OTC bodybuilding supplements49
Q&A
50
What are the hormonal options available to MASCULINIZE a transgender patient?1
How do you chose between options?2
21/03/2018
26
TESTOSTERONE
http://www.rainbowhealthontario.ca/TransHealthGuide/pdf/rho_transprimarycare_masculinizinghtguide.pdf 51
TESTOSTERONE OPTIONS
• ORAL
• TRANSDERMAL
• INTRANASAL
• INJECTABLE
52
21/03/2018
27
http://www.rainbowhealthontario.ca/TransHealthGuide/pdf/masc-ht-expectedeffectsguide.pdf 53
Q&A
54
What are the most common challenges with hormonal masculinization?1
21/03/2018
28
CHALLENGES
• SUPRAPHYSIOLOGIC EFFECTS
• Testosterone side effects − ACNE− MALE PATTERN BALDNESS− MOOD/LIBIDO
55
SAM (REVISITED)
• Testosterone 100mg IM weekly
• Testosterone trough level 20.5 nmol/L ( male range 8 – 29 nmol/L)
• Hematocrit 52% L/L
• HDL dropped approx. 30% - remains just above 1.0 mml/L
56
21/03/2018
29
Q&A
57
Do all transgender patients get surgery?1
SOME ESTIMATES…..
• “Top surgery” /mastectomy >95%,
• TVH/BSO (Total vaginal hysterectomy with or without bilateral salpingoorphorectomy) 50-60% (maybe more??)
• Phallo/metoidioplasty ~15%
• FFS (Facial feminization surgery including tracheal shave) ~5% (likely more would do if public coverage)
• BA (Breast augmentation) 5-10% (again, more would likely consider if not private)
• Vocal chord surgery 1%
• Orchiectomy 5-10%
• Vaginoplasty >75%
• Hair removal (laser) ?50%
58
21/03/2018
30
Q&A
59
What are possible surgeries for gender transition?
1
GENDER TRANSITION SURGERIES “MENU”
Masculinizing surgeries
• Bilateral mastectomy with chest reconstruction
• Hysterectomy with/without bilateral salpingoophorectomy
• metoidioplasty
• phalloplasty
Feminizing surgeries
• Breast surgery / augmentation
• Orchiectomy
• Vaginoplasty
• Facial Feminization Surgery (FFS)
• Cricothyroid shaving / Cricothyroidectomy
• Vocal chord
60
21/03/2018
31
GENDER TRANSITION SURGERIES MASCULINIZING (FTM)
Bilat mastectomy with chest “contouring” / reconstruction
61
GENDER TRANSITION SURGERIESMASCULINIZING (FTM)
• Hysterectomy with/without bilateral salpingoorphorectomy
62
21/03/2018
32
GENDER TRANSITION SURGERIESMASCULINIZING (FTM)
• Metoidioplasty (meto, meta)
63
GENDER TRANSITION SURGERIESMASCULINIZING (FTM)
• Phalloplasty (phallo)
64
21/03/2018
33
GENDER TRANSITION SURGERIESFEMINIZING (MTF)
• Breast surgery / augmentation
65
GENDER TRANSITION SURGERIESFEMINIZING (MTF)
• Orchiectomy
66
21/03/2018
34
GENDER TRANSITION SURGERIESFEMINIZING (MTF)
• Vaginoplasty
67
GENDER TRANSITION SURGERIESFEMINIZING (MTF)
• Facial Feminization Surgery (FFS)
68
21/03/2018
35
GENDER TRANSITION SURGERIESFEMINIZING (MTF)
• Cricothyroid shaving / Cricothyroidectomy
69
GENDER TRANSITION SURGERIESFEMINIZING (MTF)
• Vocal chord surgeries
70
21/03/2018
36
Q&A
71
What is the typical post-op course / experience?
1
What are the typical complications, if any?2
• Cosmetic appearance (less than ideal – mastectomy/ chest contouring, phallo)
• Multiple procedures to accomplish (phallo)
• Post op wound care / infections
• Elaborate post op care (dilatations)
• Poor functionality (vaginoplasty, phallo)
• Surgical complications – e.g. urethral stricture - phallo
72
21/03/2018
37
DISCUSSION
73
THANKS!c o n t a c t @ d r t e d j a b l o n s k i . c o m
74
21/03/2018
38
RESOURCES
LOCAL
• Organizations, on line support groups
• Specialized clinics, FP “champions” with special interest /specialists with interest
PROVINCIAL
• www.sherbourne.on.ca
• www.rainbowhealthontario.ca/resource-search
• http://www.rainbowhealthontario.ca/TransHealthGuide/
• www.transhealth.vch.ca
NATIONAL
• C-path www.cpath.ca
INTERNATIONAL
• W-path www.wpath.org
• www.transhealth.ucsf.edu
75
21/03/2018
39
GUIDELINES - CANADIAN
• www.cpath.ca
• www.transhealth.vch.ca
• http://www.rainbowhealthontario.ca/TransHealthGuide/#guidelines
77
ONLINE TRAINING
• http://www.rainbowhealthontario.ca/training
• http://www.rainbowhealthontario.ca/introduction-to-lgbt
78
21/03/2018
40
OTHER USEFUL WEB LINKS
• http://www.rainbowhealthontario.ca/about-lgbtq-health/
79